News

Lyric Completes Enrollment in Phase 2 PROMOTE Study of LP101 (Ulimorelin) in Enteral Feeding Intolerance
Lyric Completes Enrollment in Phase 2 PROMOTE Study of LP101 (Ulimorelin) in Enteral Feeding Intolerance
by

SOUTH SAN FRANCISCO, March 5, 2018 — Lyric Pharmaceuticals, Inc. (Lyric), a biopharmaceutical company, today announced the completion of enrollment of PROMOTE, an international, multicenter, randomized, controlled Phase 2 study of LP101 (ulimorelin) for the treatment of enteral feeding intolerance (EFI) in critically ill patients. LP101, a macrocyclic agonist of the hormone ghrelin, is under development for the treatment of

Lyric Pharmaceuticals Presents Data at ASPEN Conference on the Incidence of Enteral Feeding Intolerance in the ICU
Lyric Pharmaceuticals Presents Data at ASPEN Conference on the Incidence of Enteral Feeding Intolerance in the ICU
by

Lyric Chief Medical Officer Also Presenting on Role of Ghrelin Agonists in Critical Care SOUTH SAN FRANCISCO, CA, January 23, 2018 – Lyric Pharmaceuticals, Inc (Lyric), a biopharmaceutical company, today announced the presentation at the ASPEN 2018 Nutrition Science and Practice Conference in Las Vegas, NV of data from a prospective study on the incidence of enteral feeding intolerance (EFI) in

Lyric Pharma Granted FDA Fast Track Designation for Lead Product Ulimorelin for Enteral Feeding Intolerance (EFI)
Lyric Pharma Granted FDA Fast Track Designation for Lead Product Ulimorelin for Enteral Feeding Intolerance (EFI)
by

Lyric Chief Medical Officer to Present EFI Incidence Data and Role of Ghrelin Agonists in Critical Care at ASPEN 2018 Conference SOUTH SAN FRANCISCO, CA, January 17, 2018 – Lyric Pharmaceuticals, Inc (Lyric), a biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of ulimorelin (LP101) for the

Lyric Pharmaceuticals Announces $20.4M Series A Funding Round
Lyric Pharmaceuticals Announces $20.4M Series A Funding Round
by

SOUTH SAN FRANCISCO, CA, February 26, 2015 – Lyric Pharmaceuticals Inc. today announced the initial closing of a Series A financing round totaling $20.4 million. The financing, co-led by RiverVest Venture Partners, Santé Ventures and Third Point Ventures, includes participation by Aperture Venture Partners. Lyric is a clinical-stage pharmaceutical company co-founded in 2013 by David Wurtman, M.D., M.B.A., President &